Company Overview - Moderna is a leading developer of messenger RNA vaccines and medicines [2] - The company has faced pressure on its shares over the last couple of years, particularly due to decreasing immunization rates following its role in the COVID pandemic [2] Recent Challenges - There has been a notable decline in immunization rates, impacting Moderna's market performance [2] - The FDA and public figures have raised concerns about mRNA vaccines, contributing to a challenging environment for the company [2] - A recent setback related to a product has added to the difficulties faced by Moderna [2] Future Prospects - Moderna recently held an R&D Day, showcasing new vaccines and medicines in development, indicating a potentially exciting future for the company [2] - The financial strategies and developments discussed during the R&D Day suggest a focus on innovation and growth moving forward [2]